|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2011-5-6
|
|
pubmed:abstractText |
CCAAT/enhancer binding protein-? (CEBPA) mutations in acute myeloid leukemia (AML) patients with a normal karyotype (NK) confer favorable prognosis, whereas NK-AML patients per se are of intermediate risk. This suggests that blocked CEBPA function characterizes NK-AML with favorable outcome. We determined the prognostic significance of CEBPA DNA binding function by enzyme-linked immunosorbent assay in 105 NK-AML patients. Suppressed CEBPA DNA binding was defined by 21 good-risk AML patients with inv(16) or t(8;21) (both abnormalities targeting CEBPA) and 8 NK-AML patients with dominant-negative CEBPA mutations. NK-AML patients with suppressed CEBPA function showed a better overall survival (P = .0231) and disease-free survival (P = .0069) than patients with conserved CEBPA function. Suppressed CEBPA DNA binding was an independent marker for better overall survival and disease-free survival in a multivariable analysis that included FLT3-ITD, NPM1 and CEBPA mutation status, white blood cell count, age and lactate dehydrogenase. These data indicate that suppressed CEBPA function is associated with favorable prognosis in NK-AML patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AML1-ETO fusion protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CBFbeta-MYH11 fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/CCAAT-Enhancer-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/CEBPA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Core Binding Factor Alpha 2 Subunit,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Fusion,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
5
|
|
pubmed:volume |
117
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4881-4
|
|
pubmed:meshHeading |
pubmed-meshheading:21389317-Adolescent,
pubmed-meshheading:21389317-Adult,
pubmed-meshheading:21389317-Aged,
pubmed-meshheading:21389317-Base Sequence,
pubmed-meshheading:21389317-CCAAT-Enhancer-Binding Proteins,
pubmed-meshheading:21389317-Core Binding Factor Alpha 2 Subunit,
pubmed-meshheading:21389317-DNA, Neoplasm,
pubmed-meshheading:21389317-Female,
pubmed-meshheading:21389317-Humans,
pubmed-meshheading:21389317-Kaplan-Meier Estimate,
pubmed-meshheading:21389317-Karyotyping,
pubmed-meshheading:21389317-Leukemia, Myeloid, Acute,
pubmed-meshheading:21389317-Male,
pubmed-meshheading:21389317-Middle Aged,
pubmed-meshheading:21389317-Mutation,
pubmed-meshheading:21389317-Oncogene Proteins, Fusion,
pubmed-meshheading:21389317-Prognosis,
pubmed-meshheading:21389317-RNA, Messenger,
pubmed-meshheading:21389317-RNA, Neoplasm,
pubmed-meshheading:21389317-U937 Cells,
pubmed-meshheading:21389317-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
|
|
pubmed:affiliation |
Department of Internal Medicine and Clinical Research, University of Bern, Bern, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
